Trial Profile
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Glimepiride
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 25 Sep 2020 Preliminary results (n=41) assessing effect of dapagliflozin on measures of cardiovascular autonomic neuropathy and cardiac function as assessed by the B type natriuretic peptide in patients with Type 2 Diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 19 Nov 2019 Status changed from active, no longer recruiting to completed.
- 04 Feb 2019 Status changed from recruiting to active, no longer recruiting.